红日药业：股东及高管拟减持不超1.57%股份

Core Viewpoint - Major shareholders of Hongri Pharmaceutical plan to reduce their holdings, indicating potential liquidity needs and market activity [1] Shareholder Reduction Plans - Shareholder Yao Xiaoqing intends to reduce holdings by up to 46.9363 million shares, approximately 1.5624% of total equity, within three months after the announcement [1] - Senior management member Chen Ruiqiang plans to reduce holdings by up to 169,000 shares, about 0.0056% of total equity [1] - Another senior management member, Zhang Kun, plans to reduce holdings by up to 232,000 shares, approximately 0.0077% of total equity [1] Reasons for Reduction - The stated reason for all reductions is personal funding needs, with the method of reduction being through centralized bidding or block trading [1]